Neurovive (NEVPF) 5.8900 $NEVPF
NeuroVive Pharmaceutical reports change in number of shares and votes
M2 - Wed Apr 01, 3:08AM CDT
NeuroVive Pharmaceutical AB (STO:NVP), the mitochondrial medicine company, announced on Tuesday that the number of shares and votes of the company, registered with the Swedish Companies Registration Office, has increased by 1,300,000.
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - at Seeking Alpha - Sun Feb 15, 10:14AM CST
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 55.94 (+1.34), MRK: 57.25 (-0.18), QGEN: 25.45 (+0.10), CBMG: 28.95 (+1.47)
OnCore Biopharma and Tekmira Pharmaceuticals Files for Merger - Releases Further Details about License Agreement With NeuroVive
Business Wire - Thu Feb 05, 2:28AM CST
Regulatory News:
TKMR: 18.19 (+0.59)
Neurovive Pharmaceutical: NeuroVive and Skane University Hospital Initiate Collaboration on Clinical Phase II Study on Kidney Protection During Heart Surgery
Business Wire - Tue Dec 02, 1:40AM CST
Regulatory News:
NeuroVive reduces loss in third quarter 2014
M2 - Thu Nov 20, 4:57AM CST
NeuroVive Pharmaceutical AB (STO:NVP) on Wednesday reported loss before tax of SEK3,761,000, or diluted loss per share of SEK0.18, for the third quarter of 2014, from 1 July 2014 to 30 September 2014.
Global Reperfusion Injury Therapeutic Pipeline Review, H1 2014 - 7 Companies & 15 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffkhq3/reperfusion) has announced the addition of the "Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - NeuroVive Pharmaceutical AB - Scynexis, Inc. - Apeptico Forschung und Entwicklung GmbH - Stealth Peptides Inc. - Eustralis Pharmaceuticals Ltd - Nyken BV - Vasade Biosciences, Inc. Drug Profiles - cyclosporine - MTP-131 - GNX-5086 - bucillamine - Recombinant Protein to Inhibit CXCL for Cardiovascular and CNS Disorders - EUC-002 - AP-301 - NYK-1112 - Type 5 Adenylyl Cyclase Inhibitors - Small Molecule for Reperfusion Injury - MitoSNO - PVIIA - RIIIK - Small Molecules to Inhibit Cyclophilin D for Ischemia Reperfusion Injury, Neurodegenerative Diseases, And Trauma - Synthetic Peptides to Activate Complement C3 for Immunology, Cardiovascular and CNS Disorders For more information visit http://www.researchandmarkets.com/research/ff...eperfusion
NeuroVive Pharmaceutical reports change in number of shares and votes
M2 - Wed Apr 01, 3:08AM CDT
NeuroVive Pharmaceutical AB (STO:NVP), the mitochondrial medicine company, announced on Tuesday that the number of shares and votes of the company, registered with the Swedish Companies Registration Office, has increased by 1,300,000.
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - at Seeking Alpha - Sun Feb 15, 10:14AM CST
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 55.94 (+1.34), MRK: 57.25 (-0.18), QGEN: 25.45 (+0.10), CBMG: 28.95 (+1.47)
OnCore Biopharma and Tekmira Pharmaceuticals Files for Merger - Releases Further Details about License Agreement With NeuroVive
Business Wire - Thu Feb 05, 2:28AM CST
Regulatory News:
TKMR: 18.19 (+0.59)
Neurovive Pharmaceutical: NeuroVive and Skane University Hospital Initiate Collaboration on Clinical Phase II Study on Kidney Protection During Heart Surgery
Business Wire - Tue Dec 02, 1:40AM CST
Regulatory News:
NeuroVive reduces loss in third quarter 2014
M2 - Thu Nov 20, 4:57AM CST
NeuroVive Pharmaceutical AB (STO:NVP) on Wednesday reported loss before tax of SEK3,761,000, or diluted loss per share of SEK0.18, for the third quarter of 2014, from 1 July 2014 to 30 September 2014.
Global Reperfusion Injury Therapeutic Pipeline Review, H1 2014 - 7 Companies & 15 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffkhq3/reperfusion) has announced the addition of the "Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - NeuroVive Pharmaceutical AB - Scynexis, Inc. - Apeptico Forschung und Entwicklung GmbH - Stealth Peptides Inc. - Eustralis Pharmaceuticals Ltd - Nyken BV - Vasade Biosciences, Inc. Drug Profiles - cyclosporine - MTP-131 - GNX-5086 - bucillamine - Recombinant Protein to Inhibit CXCL for Cardiovascular and CNS Disorders - EUC-002 - AP-301 - NYK-1112 - Type 5 Adenylyl Cyclase Inhibitors - Small Molecule for Reperfusion Injury - MitoSNO - PVIIA - RIIIK - Small Molecules to Inhibit Cyclophilin D for Ischemia Reperfusion Injury, Neurodegenerative Diseases, And Trauma - Synthetic Peptides to Activate Complement C3 for Immunology, Cardiovascular and CNS Disorders For more information visit http://www.researchandmarkets.com/research/ff...eperfusion
